AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
Date of Report: August 11, 2015
Company: AYTU BIOSCIENCE, INC. (Delaware)
Event: Entry into a Material Definitive Agreement (Item 1.01) and Creation of a Direct Financial Obligation (Item 2.03).
The company closed the second tranche of a private placement for convertible promissory notes. This filing details the terms of the notes, the use of proceeds, and the obligations created.
Key Financial Metrics
- Capital Raised (Current Closing): Approximately $1.2 million in aggregate principal amount.
- Capital Raised (Prior Closing): Approximately $2.0 million (closed July 22, 2015).
- Total Raised to Date: Approximately $3.2 million.
- Target Offering Size: Up to $6.0 million (no assurance of reaching maximum).
- Debt Instrument: Unsecured convertible promissory notes.
- Maturity Date: January 22, 2017 (with a discretionary 6-month extension option).
- Interest Rates:
- 8% simple interest per annum for the first six months.
- 12% simple interest per annum thereafter if not converted.
- 14% simple interest per annum if a registration statement is not filed within six months.
- Conversion Price: $4.63 per share (subject to adjustment in certain financing scenarios).
- Conversion Premium: 120% of principal and accrued interest.
- Placement Agent Fees: 8% of gross proceeds plus a warrant for 8% of gross proceeds (cashless exercise).
Material Changes and Obligations
The company has incurred a new direct financial obligation of $1.2 million. Unlike the prior period, this filing confirms the closing of the second tranche of the offering. The notes are unsecured and subject to acceleration upon customary events of default. Interest is payable in cash or in kind at the company's discretion.
Registration Obligation: The company agreed to file a Form S-1 registration statement within five months of closing (by January 2016) and use best efforts to have it declared effective within 12 months of the initial closing (by July 2016).
Guidance, Outlook, and Use of Proceeds
Use of Proceeds:
- Conduct clinical studies for Zertane and RedoxSYS.
- Working capital to begin commercializing FDA-approved ProstaScint.
- General corporate purposes.
Qualified Financing Trigger: If the company completes a public offering raising at least $5.0 million in gross proceeds prior to maturity, noteholders are obligated to convert their notes into equity at the lower of the offering price or $4.63 per share.
Liquidity Event: In the event of a sale of the company, noteholders may elect to receive principal plus accrued interest plus 25% of the original principal, or the consideration on an as-converted basis.
Investor Verification Checklist
- Verify the total outstanding debt balance including the $1.2 million from this closing and the $2.0 million from the July 2015 closing.
- Confirm the status of the Form S-1 registration statement filing deadline (within 5 months of August 11, 2015).
- Assess the company's cash runway relative to the $6.0 million fundraising target and current burn rate for clinical trials.
- Review the dilution impact of the 120% conversion premium and the placement agent warrants.
- Monitor for any "Qualified Financing" events that would trigger mandatory conversion of the notes.